CoChat

Dopamine Type-1 Receptor Binding in Major Depressive Disorder Assessed Using Positron Emission Tomography and [11C]NNC-112

Open access
Cannon, Dara M, Klaver, Jacqueline M, Peck, Summer A, Rallis-Voak, Denise, Erickson, Kristine, Drevets, Wayne C · 2009 · Neuropsychopharmacology
Cited by 118

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

The dopamine type-1 receptor has been implicated in major depressive disorder (MDD) by clinical and preclinical evidence from neuroimaging, post mortem, and behavioral studies. To date, however, selective in vivo assessment of D1 receptors has been limited to the striatum in MDD samples manifesting anger attacks. We employed the PET radioligand, [11C]NNC-112, to selectively assess D1 receptor binding in extrastriatal and striatal regions in a more generalized sample of MDD subjects. The [11C]NNC-112 nondisplaceable binding potential (BPND) was assessed using PET in 18 unmedicated, currently depressed subjects with MDD and 19 healthy controls, and compared between groups using MRI-based region-of-interest analysis. The mean D1 receptor BPND was reduced (14%) in the left middle caudate of the MDD group relative to control group (p<0.05). Among the MDD subjects D1 receptor BPND in this region correlated negatively with illness duration (r=−0.53; p=0.02), and the left-to-right BPND ratio correlated inversely with anhedonia ratings (r=−0.65, p=0.0040). The D1 receptor BPND was strongly lateralized in striatal regions (p<0.002 for main effects of hemisphere in accumbens area, putamen, and caudate). In post hoc analyses, a group-by-hemisphere-by-gender interaction was detected in the dorsal putamen, which was accounted for by a loss of the normal asymmetry in depressed women (F=7.33, p=0.01). These data extended a previous finding of decreased striatal D1 receptor binding in an MDD sample manifesting anger attacks to a sample selected more generally according to MDD criteria. Our data also more specifically localized this abnormality in MDD to the left middle caudate, which is the target of afferent neural projections from the orbitofrontal and anterior cingulate cortices where neuropathological changes have been reported in MDD. Finally, D1 receptor binding was asymmetrical across hemispheres in healthy humans, compatible with evidence that dopaminergic function in the striatum is lateralized during reward processing, voluntary movement, and self-stimulation behavior.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2008.194

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 74

  1. Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M et al (2000). Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20: 225–243. · DOI · Paper page
  2. Agren H, Reibring L (1994). PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry 27: 2–6. · DOI · Paper page
  3. Andersen PH, Gronvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C et al (1992). NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol 219: 45–52. · DOI
  4. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). APA Press: Washington, DC.
  5. Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z et al (2005). Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 89: 115–123. · DOI
  6. Asberg M, Bertilsson L, Martensson B (1984). CSF monoamine metabolites, depression, and suicide. Adv Biochem Psychopharmacol 39: 87–97.
  7. Bowden C, Theodorou A, Cheetham SC, Lowther S, Katona CL, Crompton MR et al (1997). Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res 752: 227–233. · DOI
  8. Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA et al (2003). Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA 289: 3125–3134. · DOI · Paper page
  9. Camps M, Kelly PH, Palacios JM (1990). Autoradiographic localization of dopamine D 1 and D 2 receptors in the brain of several mammalian species. J Neural Transm Gen Sect 80: 105–127. · DOI · Paper page
  10. Chou YH, Karlsson P, Halldin C, Olsson H, Farde L (1999). A PET study of D (1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology (Berl) 146: 220–227. · DOI
  11. Cortes R, Gueye B, Pazos A, Probst A, Palacios JM (1989). Dopamine receptors in human brain: autoradiographic distribution of D1 sites. Neuroscience 28: 263–273. · DOI · Paper page
  12. De Keyser J, Dierckx R, Vanderheyden P, Ebinger G, Vauquelin G (1988). D1 dopamine receptors in human putamen, frontal cortex and calf retina: differences in guanine nucleotide regulation of agonist binding and adenylate cyclase stimulation. Brain Res 443: 77–84. · DOI
  13. de la Fuente-Fernandez R, Kishore A, Calne DB, Ruth TJ, Stoessl AJ (2000). Nigrostriatal dopamine system and motor lateralization. Behav Brain Res 112: 63–68. · DOI
  14. de la Mora MP, Cardenas-Cachon L, Vazquez-Garcia M, Crespo-Ramirez M, Jacobsen K, Hoistad M et al (2005). Anxiolytic effects of intra-amygdaloid injection of the D1 antagonist SCH23390 in the rat. Neurosci Lett 377: 101–105. · DOI · Paper page
  15. Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG et al (1995). Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl) 121: 317–322. · DOI
  16. Dougherty DD, Bonab AA, Ottowitz WE, Livni E, Alpert NM, Rauch SL et al (2006). Decreased striatal D1 binding as measured using PET and [11C]SCH 23 390 in patients with major depression with anger attacks. Depress Anxiety 23: 175–177. · DOI · Paper page
  17. Drevets W (2008). Neural circuits underlying anhedonia in major depressive disorder. Biol Psychiatry 63 (7 supplement 1): 110S.
  18. Ebert D, Feistel H, Loew T, Pirner A (1996). Dopamine and depression—striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl) 126: 91–94. · DOI
  19. Ekelund J, Narendran R, Guillain O, Castrillon J, Hwang D, Slifstein M et al (2006). Pharmacological selectivity of the in vivo binding of [11C]NNC 112 and [11C]SCH 23390 in the cortex. A PET study in baboons. Neuroimage 31 (Suppl 2): T111. · doi:10.1016/j.neuroimage.2006.04.097
  20. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN et al (2007). In vivo DA D (1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9: 117–125. · DOI
  21. El-Ghundi M, Fletcher PJ, Drago J, Sibley DR, O'Dowd BF, George SR (1999). Spatial learning deficit in dopamine D (1) receptor knockout mice. Eur J Pharmacol 383: 95–106. · DOI · Paper page
  22. El-Ghundi M, O'Dowd BF, George SR (2001). Prolonged fear responses in mice lacking dopamine D1 receptor. Brain Res 892: 86–93. · DOI
  23. Ferry AT, Ongur D, An X, Price JL (2000). Prefrontal cortical projections to the striatum in macaque monkeys: evidence for an organization related to prefrontal networks. J Comp Neurol 425: 447–470. · doi:10.1002/1096-9861(20000925)425:3<447::aid-cne9>3.0.co;2-v
  24. Fibiger HC (1991). The dopamine hypothesis of schizophrenia and mood disorders. In: Willner P, Scheel-Kruger J (eds). The Mesolimbic Dopamine System: From Motivation to Action. Wiley: New York. pp 615–638.
  25. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22: 5042–5054. · DOI · Paper page
  26. Glick SD, Badalamenti JI (1986). Sex difference in reward asymmetry and effects of cocaine. Neuropharmacology 25: 633–637. · DOI
  27. Glick SD, Ross DA, Hough LB (1982). Lateral asymmetry of neurotransmitters in human brain. Brain Res 234: 53–63. · DOI · Paper page
  28. Glick SD, Weaver LM, Meibach RC (1980). Lateralization of reward in rats: differences in reinforcing thresholds. Science 207: 1093–1095. · DOI
  29. Glick SD, Weaver LM, Meibach RC (1981). Amphetamine enhancement of reward asymmetry. Psychopharmacology (Berl) 73: 323–327. · doi:10.1007/bf00426459
  30. Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J et al (1998). Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med 39: 2061–2068.
  31. Hamilton M (1959). The assessment of anxiety states by rating. Brit J Med Psychol 32: 50–55. · DOI · Paper page
  32. Hirvonen J, Karlsson H, Kajander J, Markkula J, Rasi-Hakala H, Nagren K et al (2008). Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl) 197: 581–590. · DOI
  33. Holmes A, Lachowicz JE, Sibley DR (2004). Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes. Neuropharmacology 47: 1117–1134. · DOI
  34. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H et al (2003). Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23: 1096–1112. · DOI · Paper page
  35. Iyo M, Yamasaki T (1993). The detection of age-related decrease of dopamine D1, D2 and serotonin 5-HT2 receptors in living human brain. Prog Neuropsychopharmacol Biol Psychiatry 17: 415–421. · DOI
  36. Jenkinson M, Smith S (2001). A global optimisation method for robust affine registration of brain images. Med Image Anal 5: 143–156. · DOI · Paper page
  37. Karle J, Clemmesen L, Hansen L, Andersen M, Andersen J, Fensbo C et al (1995). NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl) 121: 328–329. · DOI
  38. Kato T (2007). Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 61: 3–19. · DOI · Paper page
  39. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA (2002). Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 52: 740–748. · DOI · Paper page
  40. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W (1999). Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res 90: 91–101. · DOI
  41. Koks S, Nikopensius T, Koido K, Maron E, Altmae S, Heinaste E et al (2006). Analysis of SNP profiles in patients with major depressive disorder. Int J Neuropsychopharmacol 9: 167–174. · DOI · Paper page
  42. Lalumiere RT, Nguyen LT, McGaugh JL (2004). Post-training intrabasolateral amygdala infusions of dopamine modulate consolidation of inhibitory avoidance memory: involvement of noradrenergic and cholinergic systems. Eur J Neurosci 20: 2804–2810. · DOI · Paper page
  43. Laruelle M, Huang Y (2001). Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. Q J Nucl Med 45: 124–138.
  44. Links JM, Zubieta JK, Meltzer CC, Stumpf MJ, Frost JJ (1996). Influence of spatially heterogeneous background activity on hot object quantitation in brain emission computed tomography. J Comput Assist Tomogr 20: 680–687. · DOI · Paper page
  45. Liu ZH, Shin R, Ikemoto S (2008). Dual role of medial A10 dopamine neurons in affective encoding. Neuropsychopharmacology. February 6, 2008 · DOI
  46. ([epub ahead of print] doi: 10.1038/npp.2008.4) · DOI
  47. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C (1998). A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond) 23: 207–214. · DOI · Paper page
  48. Montgomery AJ, Stokes P, Kitamura Y, Grasby PM (2007). Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J Affect Disord 101: 113–122. · DOI
  49. Montgomery S, Asberg M (1979). A new depression scale designed to be sensitive to change. Brit J Psychiat 134: 382–389. · DOI · Paper page
  50. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL et al (2006). Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 67 (Suppl 6): 46–49.
  51. Papp M, Klimek V, Willner P (1994). Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl) 115: 441–446. · DOI · Paper page
  52. Pimoule C, Schoemaker H, Reynolds GP, Langer SZ (1985). [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol 114: 235–237. · DOI
  53. Robbins TW (2000). Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res 133: 130–138. · DOI · Paper page
  54. Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S et al (1999). Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 56: 1101–1106. · DOI · Paper page
  55. Savitz J, van der Merwe L, Solms M, Ramesar R (2007). Lateralization of hand skill in bipolar affective disorder. Genes Brain Behav 6: 698–705. · DOI
  56. Schultz W (1997). Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 7: 191–197. · DOI · Paper page
  57. Severino G, Congiu D, Serreli C, De Lisa R, Chillotti C, Del Zompo M et al (2005). A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 134B: 37–38. · DOI
  58. Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T et al (1993). Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56: 467–472. · DOI
  59. Silva MA, Topic B, Lamounier-Zepter V, Huston JP, Tomaz C, Barros M (2007). Evidence for hemispheric specialization in the marmoset (Callithrix penicillata) based on lateralization of behavioral/neurochemical correlations. Brain Res Bull 74: 416–428. · DOI
  60. Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M et al (2007). [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT (2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27: 1733–1741. · DOI
  61. Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T et al (1991). Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology (Berl) 103: 41–45. · DOI · Paper page
  62. Suzuki M, Hatano K, Sakiyama Y, Kawasumi Y, Kato T, Ito K (2001). Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and in vitro receptor autoradiography. Synapse 41: 285–293. · DOI
  63. Tavares JV, Drevets WC, Sahakian BJ (2003). Cognition in mania and depression. Psychol Med 33: 959–967. · DOI · Paper page
  64. Todd RD, Carl J, Harmon S, O'Malley KL, Perlmutter JS (1996). Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J Neurosci 16: 7776–7782. · DOI
  65. Tomer R, Goldstein RZ, Wang GJ, Wong C, Volkow ND (2008). Incentive motivation is associated with striatal dopamine asymmetry. Biol Psychol 77: 98–101. · DOI · Paper page
  66. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM et al (2002). Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10: 36–43. · DOI · Paper page
  67. Waddington JL, Clifford JJ, McNamara FN, Tomiyama K, Koshikawa N, Croke DT (2001). The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion (‘knockout’). Prog Neuropsychopharmacol Biol Psychiatry 25: 925–964. · DOI
  68. Wang Y, Chan GL, Holden JE, Dobko T, Mak E, Schulzer M et al (1998). Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse 30: 56–61. · DOI
  69. Willner P (1995). Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, pp 921–932.
  70. Willner P (2000). Dopaminergic mechanisms in depression and mania. In: Bloom FaK, D (ed). Neuropsychopharmacology. The Fourth Generation of Progress, Raven Press, New York.
  71. Woods RP, Cherry SR, Mazziotta JC (1992). Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16: 620–633. · DOI · Paper page
  72. Yamamoto BK, Lane RF, Freed CR (1982). Normal rats trained to circle show asymmetric caudate dopamine release. Life Sci 30: 2155–2162. · DOI
  73. Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT et al (2008). Greater availability of dopamine transporters in patients with major depression—a dual-isotope SPECT study. Psychiatry Res 162: 230–235. · DOI
  74. Zarate Jr CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD et al (2004). Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 56: 54–60. · DOI · Paper page

Cited by

Metadata

Authors
Cannon, D. M., Klaver, J. M., Peck, S. A., Rallis-Voak, D., Erickson, K., & Drevets, W. C.
Venue
Neuropsychopharmacology
Published
2008-10-22
Volume
34
Issue
5
Pages
1277-1287
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2023193193
Cited by
118
References
23
FWCI
3.24
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.